<code id='9B93B6822B'></code><style id='9B93B6822B'></style>
    • <acronym id='9B93B6822B'></acronym>
      <center id='9B93B6822B'><center id='9B93B6822B'><tfoot id='9B93B6822B'></tfoot></center><abbr id='9B93B6822B'><dir id='9B93B6822B'><tfoot id='9B93B6822B'></tfoot><noframes id='9B93B6822B'>

    • <optgroup id='9B93B6822B'><strike id='9B93B6822B'><sup id='9B93B6822B'></sup></strike><code id='9B93B6822B'></code></optgroup>
        1. <b id='9B93B6822B'><label id='9B93B6822B'><select id='9B93B6822B'><dt id='9B93B6822B'><span id='9B93B6822B'></span></dt></select></label></b><u id='9B93B6822B'></u>
          <i id='9B93B6822B'><strike id='9B93B6822B'><tt id='9B93B6822B'><pre id='9B93B6822B'></pre></tt></strike></i>

          
          WSS
          This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market.
          Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

          The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

          Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

          advertisement

          The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion